• News

      Recent news on Salspera

        FDA GRANTS FAST TRACK DESIGNATION TO SALSPERA'S SALTIKVA, AN INNOVATIVE IMMUNOTHERAPEUTIC APPROACH TO TREAT METASTATIC PANCREATIC CANCER
      June 1, 2022
      Salspera today announced the U.S. Food and Drug Administration (FDA) granted Fast Track...
        FDA GRANTS ORPHAN DRUG DESIGNATION (ODD) TO SALSPERA'S SALTIKVA, AN INNOVATIVE IMMUNOTHERAPEUTIC APPROACH TO TREAT METASTATIC PANCREATIC CANCER
      May 23, 2022
      Salspera today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug...
      Salspera Announces Positive Topline Data in Phase 2 Trial of Saltikva in Metastatic Pancreatic Cancer
      September 27, 2021
      Oakdale, MN, September 27th, 2021 – Salspera, LLC, a clinical stage biotechnology developing...
      More Posts
      All Posts
      ×
      Cookie Use
      We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
      Learn More